pipe-791
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 26, 2023 (NCT05983939)
Timeline
Indications
Mechanism of action
- Lysophosphatidic acid receptor Edg-2INHIBITOR
LPAR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07284459 | Phase 2 | Dec 31, 2025 | Contineum Therapeutics |
| NCT06810245 | Phase 1 | Feb 4, 2025 | Contineum Therapeutics |
| NCT06683612 | Phase 1 | Nov 30, 2024 | Contineum Therapeutics |
| NCT05983939 | Phase 1 | Jun 26, 2023 | Contineum Therapeutics, Pipeline Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Contineum Therapeutics | For profit | 4 | 4 | 2 | 2023 |
| Pipeline Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1